CVS Health Reaffirms FY23 Outlook: Adjusted EPS $8.50 - $8.70 Vs. $8.63 Estimate, GAAP EPS $6.90 - $7.12
Portfolio Pulse from Benzinga Newsdesk
CVS Health's senior management team is scheduled to participate in a webcast on May 31, 2023, and reaffirm the company's FY23 GAAP EPS guidance range of $6.90 to $7.12, Adjusted EPS guidance range of $8.50 to $8.70, and cash flow from operations guidance range of $12.5 billion to $13.5 billion.
May 31, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CVS Health reaffirms its FY23 outlook, including GAAP EPS of $6.90-$7.12, Adjusted EPS of $8.50-$8.70, and cash flow from operations of $12.5B-$13.5B.
CVS Health's reaffirmation of its FY23 outlook is in line with expectations, which should not cause any significant short-term price movement. The company's outlook includes GAAP EPS, Adjusted EPS, and cash flow from operations, which are important financial metrics for investors. However, since this reaffirmation is not a new development or a surprise, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100